Skip to main content
Fig. 2 | Experimental Hematology & Oncology

Fig. 2

From: MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors

Fig. 2

Progression-free survival in patients. a Progression-free survival in all patients (n  =  40). b Progression-free survival between MET amplification/non-amplification by FISH (n = 40). c Progression-free survival between MET GCN ≥  5/GCN <  5 by NGS (n = 40). d Progression-free survival between MET focal amplification/non-focal amplification by NGS (n  = 35)

Back to article page